{"filings":[{"id":2106242,"accession_number":"0001104659-26-092025","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-08-06T20:16:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q2 net loss $14.9M; proposes all-stock merger with Avere Therapeutics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Definitive all-stock merger with Avere Therapeutics; combined co to trade as AVRX; concurrent $320M private financing.","Cash, equivalents, and marketable securities $20.1M at June 30, 2026, down from $41.8M at Dec 31, 2025.","Net loss $14.9M for Q2 2026 vs $26.8M for Q2 2025; R&D expenses fell to $7.4M from $24.1M.","Asset impairment costs of $5.1M from restructuring initiatives to reduce footprint and sell assets.","LigaChem elected to continue LNCB74 development; NextCure eligible for future milestones and royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1619077,"accession_number":"0001104659-26-083326","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-07-14T11:00:58+00:00","items":["1.01","2.05","5.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure to reverse merge with Avere; Avere holders get ~98% of combined co; $320M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["NextCure (NXTC) to acquire Avere Therapeutics via reverse merger; Avere stockholders will own ~98.11% of combined company; NextCure stockholders ~1.89%.","Concurrent $320M private placement from institutional investors into Avere; condition of at least $150M proceeds at close.","NextCure to reduce workforce by substantial majority; expects ~$1.9M one-time charges in Q3 2026.","NextCure halts new patient enrollment in SIM0505 ADC study in US; opts out of cost-sharing for LNCB74 ADC; not due to safety/efficacy.","Pre-merger NextCure stockholders to receive CVRs entitling them to 90% of proceeds from future monetization of legacy assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1259118,"accession_number":"0001104659-26-077546","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-06-25T12:01:26+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NextCure shareholders elect directors, approve amended equity plan with 80,000 additional shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anne Borgman, M.D. and John G. Houston, Ph.D. reelected as Class I directors for 3-year terms.","Shareholders approved amendment and restatement of 2019 Omnibus Incentive Plan, increasing authorized shares by 80,000.","Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 passed with 2,774,832 votes for.","Advisory vote on executive compensation passed with 2,109,269 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759796,"accession_number":"0001104659-26-068604","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-06-01T12:10:58+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 55% (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 wks follow-up; 52.9% in ovarian, 66.7% in USC.","TEAEs leading to dose discontinuation in 3 patients (Gr2 ILD, Gr3 fungal pneumonia, Gr4 thrombocytopenia); no primary prophylaxis for hematologic toxicities used.","Patients heavily pretreated: median 5 prior systemic regimens (range 1-12); 78% ovarian cancer.","Cash, cash equivalents and marketable securities expected to fund operations into Q1 2027.","Virtual KOL event scheduled for June 2, 2026 at 8 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94498,"accession_number":"0001104659-26-057171","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports Q1 net loss $9.8M; cash $29.7M; SIM0505 Fast Track & ASCO data in June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $29.7M at March 31, 2026, down $12.1M from year-end; runway into H1 2027 through proof-of-concept for SIM0505.","Net loss $9.8M (vs $11.0M YoY); R&D $6.8M, G&A $3.3M, both down vs prior year.","SIM0505 (CDH6 ADC) granted FDA Fast Track for platinum-resistant ovarian cancer; Phase 1 dose optimization initiated May 2026.","Initial Phase 1 dose escalation data for SIM0505 to be presented at ASCO 2026 on June 1, 2026, including US and China patients.","LNCB74 (B7-H4 ADC) Phase 1 dose escalation enrollment ongoing; trial progress update expected in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106925,"accession_number":"0001104659-26-024121","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports FY2025 net loss of $55.8M; cash $41.8M; SIM0505 data expected Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities at Dec 31, 2025: $41.8M, down from $68.6M a year ago.","Net loss for FY2025: $55.8M, roughly flat vs $55.7M in FY2024; R&D expenses rose to $44.9M.","SIM0505 (CDH6 ADC) Phase 1 dose escalation data and dose optimization start in ovarian cancer both expected Q2 2026.","LNCB74 (B7-H4 ADC) Phase 1 dose escalation update anticipated in second half of 2026.","Company expects current resources to fund operations into first half of 2027 through proof-of-concept for SIM0505."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106924,"accession_number":"0001104659-26-006021","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.","SIM0505 (CDH6 ADC) Phase 1 dose escalation data expected Q2 2026; dose optimization starts H1 2026.","LNCB74 (B7-H4 ADC) higher dose cohorts underway; proof-of-concept data delayed from H1 to H2 2026.","Both programs target gynecological cancers; LNCB74 now includes adenoid cystic carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123251,"accession_number":"0001104659-25-123305","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NextCure enters ATM agreement for up to $14.5M common stock offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement allows sale of up to $14.5M of common stock at market prices, effective December 19, 2025.","Agent H.C. Wainwright receives 3.0% compensation on gross proceeds from shares sold.","Net proceeds to fund general corporate purposes, including preclinical studies and clinical trials.","Sales may be made on Nasdaq or in negotiated transactions; no minimum price or volume commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123250,"accession_number":"0001104659-25-112975","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure closes $21.5M PIPE led by Ikarian, Squadron; extends cash runway into H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$21.5M from PIPE closed Nov 14, 2025; 708,428 shares at $8.52 and 1,815,049 pre-funded warrants at $8.519.","Lead investors: Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, Exome Asset Management; H.C. Wainwright placement agent.","Cash runway extended into H1 2027, beyond planned H1 2026 POC data readouts for SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC).","Registration rights agreement entered to file resale registration statement with SEC for the sold securities.","Management believes existing cash, equivalents, and marketable securities sufficient to fund operations into first half of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123249,"accession_number":"0001104659-25-107008","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.","Net loss $8.6M in Q3 2025 vs $11.5M in Q3 2024; R&D spend down to $6.1M from $8.8M.","SIM0505 (CDH6 ADC) US enrollment began Oct 2025 at mid-tier dose; PoC data readout expected H1 2026.","LNCB74 (B7-H4 ADC) received FDA protocol amendment for higher dose cohorts; PoC data also H1 2026.","$12M upfront license fee to Simcere Zaiming for SIM0505 rights contributed to cash burn."],"consensus_eps_estimate":null,"consensus_eps_actual":-18.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139930,"accession_number":"0001558370-25-011752","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NextCure CSO resigns effective Sept 1, 2025; no replacement named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Solomon Langermann, Ph.D., resigned as Chief Scientific Officer, effective September 1, 2025.","Resignation was not due to any disagreement with the Company or its operations.","No successor has been announced at this time.","Board and Company thanked Dr. Langermann for his contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139929,"accession_number":"0001558370-25-010774","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.","First US patient dosing for SIM0505 expected in Q3 2025; Phase 1 data in China showed partial response.","LNCB74 (B7-H4 ADC) Phase 1 in cohort 4; backfill cohorts planned H2 2025.","Cash $35.3M as of June 30, 2025; expects to fund operations into mid-2026.","Simcere Zaiming made $2M equity investment; regained Nasdaq minimum bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139928,"accession_number":"0001558370-25-009214","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"NextCure effects 1:12 reverse stock split effective July 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1:12, effective 12:01 a.m. ET on July 14, 2025.","Stockholders approved split ratio range of 1:5 to 1:15; Board chose 1:12.","No fractional shares; cash payment for fractional shares based on closing price prior to effective date.","Authorized shares remain 100 million; all outstanding options, warrants, and equity plans adjusted proportionally.","Common stock continues trading under ticker NXTC on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139927,"accession_number":"0001558370-25-009163","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NextCure approves 1-for-12 reverse stock split effective July 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1:12 reverse stock split; effective July 14, 2025 with split-adjusted trading at market open.","Every 12 shares convert into 1 share; fractional shares paid in cash based on prior day's closing price.","Outstanding equity awards, incentive plans, and exercise prices adjusted proportionally to the split.","No change to common stock par value; trading symbol remains NXTC on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157531,"accession_number":"0001558370-25-008789","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NextCure stockholders elect directors, ratify auditor, approve reverse stock split at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors David Kabakoff, Michael Richman, and Stephen W. Webster for three-year terms expiring 2028.","Ratified Ernst & Young LLP as independent auditor for fiscal year 2025 with 18.8M for, 1.4M against.","Approved say-on-pay (11.3M for, 0.4M against) and frequency vote of every year (11.7M for).","Approved amendment to certificate of incorporation to authorize reverse stock split when determined by the Board (18.2M for, 2.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157530,"accession_number":"0001558370-25-008633","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure licenses ADC SIM0505 from Simcere Zaiming in deal worth up to $745M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $12M + $5M payable upon financing or by Dec 31, 2025; milestones up to $745M plus tiered royalties up to double digits.","Private placement: Simcere affiliate buys 4,063,633 shares at $0.492/share for $2M; registration rights granted.","SIM0505 (CDH6-targeting ADC) in Phase 1 in China; US Phase 1 expected Q3 2025 with initial data in H1 2026.","NextCure also obtains non-exclusive license to Simcere's linker/payload for a novel target ADC; Simcere retains Greater China rights.","Cash runway into mid-2026 based on current resources; company expects to exhaust sooner if assumptions prove incorrect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157529,"accession_number":"0001558370-25-006106","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.","Net loss $11.0M vs $17.1M YoY; R&D expense $7.9M vs $11.4M YoY due to 2024 restructuring.","LNCB74 (B7-H4 ADC) Phase 1 cleared cohort 2, dosing cohort 3; backfill cohorts planned H2 2025.","Proof-of-concept data readout for LNCB74 planned in first half of 2026.","Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis imperfecta) seeking partners; IND filings possible in 12-18 months if funded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157528,"accession_number":"0001558370-25-004651","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure updates corporate presentation on LNCB74 trial; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation for LNCB74, a clinical-stage candidate, furnished on April 10, 2025.","Company engaging with investment community referencing updated materials.","No new clinical data, enrollment figures, or milestones provided in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175905,"accession_number":"0001558370-25-002396","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports FY2024 net loss of $55.7M; cash $68.6M, LNCB74 Phase 1 advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.7M in FY2024 improved from $62.7M in FY2023; R&D expenses $41.5M, G&A $15.7M, both down YoY.","Cash, equivalents, and marketable securities $68.6M at Dec 31, 2024 (vs $108.3M); expected to fund operations into H2 2026.","LNCB74 (B7-H4 ADC) Phase 1: completed cohort 1 in Feb 2025, currently dosing cohort 2; backfill cohorts planned H2 2025.","Preclinical non-oncology programs (NC181 for Alzheimer's, NC605 for osteogenesis imperfecta) seeking partnerships.","Potential IND filings for NC181 and NC605 within 12-18 months if partner or third-party funding secured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175904,"accession_number":"0001558370-25-000603","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NextCure receives Nasdaq bid price deficiency notice; has until July 30, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified NextCure that its closing bid price was below $1.00 for 30 consecutive business days.","Company has 180-day grace period ending July 30, 2025 to meet the $1.00 minimum bid for 10 consecutive days.","If not compliant, NextCure may seek an additional 180-day extension if it meets other listing standards.","The company is evaluating options including a reverse stock split; delisting risk remains.","No immediate effect on trading; stock continues trading on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175903,"accession_number":"0001558370-25-000099","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.","LNCB74 is being developed as a therapeutic for treating multiple cancers.","FDA cleared the IND for LNCB74 in December 2024.","LNCB74 is developed in partnership with LigaChem Biosciences.","Phase 1 aims to evaluate safety, tolerability, and preliminary anti-tumor activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192813,"accession_number":"0001558370-24-016108","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).","Phase 1 trial will evaluate LNCB74 for multiple cancers.","LNCB74 developed in partnership with LigaChem Biosciences under co-development agreement.","NextCure CEO Michael Richman highlighted differentiation from other B7-H4 ADCs.","IND acceptance allows NextCure to proceed with clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192812,"accession_number":"0001558370-24-016026","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure files IND for product candidate LNCB74","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Investigational New Drug application with FDA for LNCB74.","Updated corporate presentation to reflect the IND filing.","Company engaging with investment community starting December 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192811,"accession_number":"0001558370-24-015060","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure furnishes November 2024 corporate presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company hosting calls with investment community beginning Nov. 8, 2024, referencing the presentation.","Presentation furnished as Exhibit 99.1 under Regulation FD; not deemed filed.","No financial or clinical updates extracted from the exhibit text provided.","Stock ticker NXTC, listed on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192810,"accession_number":"0001558370-24-014866","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.","Cash, cash equivalents, and marketable securities $75.3M as of Sep 30, 2024; expected runway into H2 2026.","LNCB74 (B7-H4 ADC) IND planned by Q4 2024; preclinical data at SITC in November.","NC410 combo trial concluding, seeking partner; ovarian ICI-naïve response rate 25% (5/20) and CRC MSS 8.3% (3/36) PRs at 100 mg.","Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis) also seeking partner or financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209239,"accession_number":"0001558370-24-010598","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports Q2 net loss $15.4M; cash $86.4M; LNCB74 IND on track for year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M in Q2 2024 vs $17.9M in Q2 2023; R&D expenses $12.4M (down from $13.4M).","Cash & marketable securities $86.4M as of June 30, 2024; expected to fund operations into H2 2026.","LNCB74 (B7-H4 ADC) GLP tox studies completed; IND submission planned by year-end 2024.","NC410 + pembrolizumab ovarian cohort enrollment completed (16 additional patients); data expected Q4 2024.","NC181 (Alzheimer's) manufacturing initiated for tox studies; seeking partnering/funding for IND mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227174,"accession_number":"0001558370-24-009401","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NextCure shareholders reject officer exculpation amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal to amend charter to exculpate officers failed: 10,638,433 for, 2,863,486 against, 11,212 abstain.","Elaine V. Jones and Ellen G. Feigal elected as Class II directors with 11.8M and 12.9M votes for, respectively.","Ernst & Young LLP ratified as independent auditor for FY2024: 21,818,499 for, 98,189 against.","Broker non-votes of 8,403,929 on director election and exculpation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227173,"accession_number":"0001558370-24-009282","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NextCure CMO Han Myint retires July 1; becomes consultant through 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Han Myint retires as CMO effective July 1, 2024; will provide consulting services starting July 2, 2024 on clinical trials and join Scientific Advisory Board.","The Company will provide continued salary and healthcare benefits through March 31, 2025.","Equity awards continue to vest during the consulting term; exercisability period extended to 90 days after term expiration.","Consulting agreement initial term through July 2, 2025, auto-renewing annually unless terminated by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227172,"accession_number":"0001558370-24-006543","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure posts Q1 net loss of $17.1M; cash $96M; NC410 data at ASCO June 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $96.0M as of March 31, 2024, down $12.3M from Q4 2023; expected to fund operations into H2 2026.","Net loss of $17.1M for Q1 2024 vs $16.1M in Q1 2023; R&D $11.4M, G&A $4.4M, restructuring costs $2.5M.","Phase 1b NC410 combo with pembrolizumab data at ASCO June 1, including additional 20 CRC patients.","LNCB74 (B7-H4 ADC) advancing; IND submission planned by year-end with GLP tox studies initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246061,"accession_number":"0001558370-24-003671","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.","Workforce reduction ~37%; internal GMP manufacturing paused; one-time restructuring charges ~$0.8M expected in Q2 2024.","NC410 combo: 42.8% ORR (3 PRs in 7 evaluable ovarian patients); CRC cohort 10.5% ORR (2/19), median PFS 8.1 months.","LNCB74 (B7-H4 ADC) IND planned by year-end 2024; cost-sharing with LegoChem Biosciences.","Cash runway now expected into second half of 2026 following restructuring and cost reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263519,"accession_number":"0001558370-23-019766","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure discontinues NC762, prioritizes LNCB74 ADC; NC410 data expected H1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NC410 (LAIR-2 fusion) combination with pembrolizumab adding patients to 100 mg cohort for microsatellite stable colorectal cancer without liver mets; data expected H1 2024.","NC762 (B7-H4 mAb) development halted due to competitive environment and limited activity; resources shifted to LNCB74 (B7-H4 ADC).","LNCB74 set to initiate dose range-finding toxicology study and GMP manufacturing in early 2024.","NC525 (LAIR-1 mAb) Phase 1a dose escalation ongoing (4th cohort enrolled); safe and well tolerated; data expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263518,"accession_number":"0001558370-23-017418","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q3 2023 net loss $14.3M vs $18.9M YoY; cash $118.2M funds into mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $118.2M at Sep 30 2023, down $41.7M from Dec 31 2022; expects funding into mid-2025.","Net loss $14.3M for Q3 2023 vs $18.9M for Q3 2022; narrowed loss due to lower R&D and G&A costs.","R&D expenses $11.0M (down from $13.5M); G&A $4.6M (down from $5.7M).","Phase 1b updates for NC410 and NC762, and NC525 Phase 1a update expected by year end 2023.","Selected LNCB74 (B7-H4 ADC) from LegoChem collaboration; presented data on NC605 and NC181."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280740,"accession_number":"0001558370-23-013237","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q2 net loss $17.9M; cash $130.6M; Phase 1b data expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $130.6M as of June 30, 2023, down from $159.9M at Dec 31, 2022.","Net loss of $17.9M for Q2 2023, flat versus Q2 2022; R&D expense $13.4M, G&A $5.7M.","Phase 1b data for NC410, NC762 update, and NC525 Phase 1a update all expected in Q4 2023.","Existing cash expected to fund operations into mid-2025.","NC318 data from Yale Cancer Center to be presented at WCLC in September 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280739,"accession_number":"0001104659-23-082344","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NextCure director Garry A. Nicholson resigns effective August 15, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Garry A. Nicholson resigned from NextCure's board, effective August 15, 2023.","Resignation not due to any disagreement with the company or its operations, policies or practices.","Mr. Nicholson's departure is a board-level change; no replacement named in the filing.","NextCure common stock trades on Nasdaq Global Select Market under ticker NXTC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299354,"accession_number":"0001104659-23-074450","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"NextCure adopts amended bylaws, elects three directors, ratifies auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaws amended June 22, 2023 to incorporate Delaware law updates and universal proxy rule requirements.","Stockholders elected Class I directors Anne Borgman, John G. Houston, and Garry A. Nicholson.","Ratified Ernst & Young as independent auditor for fiscal year ending Dec 31, 2023 (19.67M for, 155k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299353,"accession_number":"0001558370-23-008118","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports Q1 net loss $16.1M, cash $145.5M; pipeline data expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.1M for Q1 2023 vs $20.6M loss in Q1 2022, narrowing on lower R&D expenses.","Cash $145.5M down from $159.9M; expects runway into mid-2025.","Three clinical programs (NC410, NC762, NC525) data updates expected in Q4 2023.","First patient dosed with NC525 (LAIR-1 mAb) Phase 1 in AML in Feb 2023.","R&D expenses decreased to $11.6M from $15.0M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319510,"accession_number":"0001558370-23-002694","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports FY2022 net loss of $74.7M; cash $159.9M, runway into mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $74.7M for FY2022 vs $69.4M in FY2021, driven by higher R&D expenses.","Cash, equivalents, and marketable securities $159.9M at Dec 31, 2022, down from $219.6M.","R&D expenses $54.2M (FY2022) vs $50.2M (FY2021); G&A $21.7M vs $20.6M.","NC410 Phase 1b/2 combo with pembrolizumab update expected mid-2023; NC762 update Q4 2023.","NC525 dosed first patient in Phase 1 AML trial Feb 2023; initial data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337702,"accession_number":"0001558370-22-016263","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure discontinues NC318 program; Q3 net loss $18.9M, cash runway extended to mid‑2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Discontinued NC318 development after no responses in Phase 2 monotherapy; continuing Yale combo trial.","Cash, cash equivalents and marketable securities at Sept 30, 2022: $169.2M, down from $219.6M at Dec 31, 2021.","Q3 2022 net loss $18.9M vs $17.9M in Q3 2021; R&D expense flat at $13.5M, G&A up to $5.7M.","Cash runway extended by 15 months; now expected to fund operations into mid‑2025.","Advancing NC410 Phase 1b/2 combo trial, NC525 Phase 1 expected Q1 2023, and NC762 expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355084,"accession_number":"0001104659-22-086121","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q2 net loss $17.9M; cash $185.5M funds ops into Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.9M in Q2 2022 vs $18.0M in Q2 2021; no revenue reported.","Cash, equivalents, and marketable securities $185.5M at June 30, down from $219.6M at Dec 31.","Cash runway expected to fund operations into the first quarter of 2024.","R&D expenses $12.8M (+$0.9M YoY); G&A expenses $5.3M (-$0.7M YoY).","Upcoming milestones: NC318 Phase 2 update Q4 2022, NC410/NC762 data H2 2022, NC525 IND filing Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373165,"accession_number":"0001104659-22-073939","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NextCure shareholders elect three Class III directors and ratify Ernst & Young auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected David Kabakoff (11,548,824 for, 1,187,004 against), Michael Richman (11,609,302 for, 1,124,238 against), and Stephen W. Webster (11,530,304 for, 1,202,184 against) as Class III directors.","Ratified Ernst & Young as independent auditor for FY2022 with 17,631,748 for, 53,399 against, 79,774 abstain.","Broker non-votes on director election totaled 4,783,701, with no broker non-votes on ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373164,"accession_number":"0001104659-22-056484","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports Q1 2022 net loss of $20.6M; cash at $201.3M, runway into Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.6M vs $16.5M in Q1 2021, driven by higher R&D expenses.","Cash, cash equivalents and securities of $201.3M, down $18.3M from Dec 2021.","On track for H2 2022 milestones: NC318 Phase 2 update, NC410 Phase 1 update, NC762 initial data, NC525 IND filing.","Cash expected to fund operations into Q1 2024.","R&D expenses $15.0M (Q1 2022) vs $12.4M (Q1 2021); G&A $5.8M vs $4.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391918,"accession_number":"0001104659-22-030025","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NextCure reports FY 2021 net loss of $69.4M; cash $219.6M, expects funding into Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.4M in 2021 vs $36.6M in 2020; no revenue recognized (Eli Lilly agreement ended).","Cash, equivalents, marketable securities $219.6M at Dec 31, 2021, down $63.8M; expected to fund ops into Q1 2024.","R&D expenses $50.2M in 2021 vs $46.6M; G&A $20.6M vs $17.0M primarily from headcount increases.","Multiple 2022 data readouts planned: NC318 Phase 2 update Q4, NC410 update H2, NC762 initial Phase 1 data H2, NC525 IND filing Q4.","COVID-19 pandemic delayed clinical trial enrollment, causing some milestones to be pushed back."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410223,"accession_number":"0001104659-21-139169","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure reports NC318 37% DCR, 5.0 mo median PFS; NC410 safe in Ph1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NC318 Phase 1/2: 37% disease control rate, median PFS 5.0 mo across all tumors; lung cohort 45% DCR, median PFS 5.2 mo.","Two NSCLC patients on NC318 >2 years: one CR at 2.8 years, one PR at 2.2 years.","Modeling predicts 800 mg weekly NC318 yields ~10x exposure; sS15 may be biomarker for patient selection.","NC410 Ph1 (n=19) up to 60 mg Q2W: no dose-limiting toxicities; shows target binding, immune modulation, ECM remodeling.","Non-clinical data: NC410 synergizes with bintrafusp alpha (TGF-β trap) for tumor control in colon cancer model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410222,"accession_number":"0001104659-21-134399","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q3 2021 net loss widens to $17.9M; cash position $235.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.9M for Q3 2021 vs $16.4M in Q3 2020, driven by higher R&D and G&A costs.","Cash, cash equivalents and marketable securities $235.3M at Sep 30, 2021, down $48.1M from Dec 31, 2020.","R&D expenses $13.6M (up from $12.7M) and G&A $4.9M (up from $4.7M) year-over-year.","Appointed Ellen G. Feigal and Anne Borgman to Board of Directors; added three new Scientific Advisory Board members.","Cash runway expected to fund operations into second half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410221,"accession_number":"0001104659-21-122499","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NextCure appoints Anne Borgman, M.D., and Ellen Feigal, M.D. to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Borgman joins as Class I director; Feigal as Class II director; both deemed independent.","Borgman serves on Nominating and Governance Committee; Feigal on Compensation Committee.","Borgman is VP at Jazz Pharmaceuticals; Feigal is Partner at NDA Partners.","Appointments follow resignation of Stella Xu, Ph.D. from the board.","New directors bring oncology and biopharma development expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429057,"accession_number":"0001104659-21-119299","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2021-09-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Stella Xu resigns from NextCure Board effective Sept 30, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stella Xu notified NextCure of her resignation from the Board of Directors.","Resignation effective September 30, 2021.","Resignation not due to any disagreement with the Company on operations, policies or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429056,"accession_number":"0001104659-21-100794","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q2 net loss $18M; cash $249.5M; trials NC318/NC410/NC762 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.0M for Q2 2021 vs $14.5M in Q2 2020; R&D $11.9M, G&A $6.0M.","Cash, equivalents & marketable securities $249.5M as of June 30, 2021; funded into H2 2023.","NC318 Phase 2 update expected Q4 2021; dosing revised to 800 mg weekly; NSCLC cohort resumed.","NC410 initial Phase 1 data expected Q4 2021; NC762 Phase 1 started, data mid-2022.","CLIA-validated assay for S15+ patient selection available for NC318 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}